Search results

4466 results

Sorted by Date . Sort by Relevance

  1. The evidence on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI raises no major safety concerns other than those associated with the TAVI procedure. However, the evidence on efficacy for preventing TAVI-related stroke is inconclusive. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG650/1 Question The evidence on percutaneous insertion of a cerebral protection device to prevent cerebral embolism

  2. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For distal DVT that does not extend into the common femoral vein the evidence on efficacy is inconclusive, therefore this procedure should only be used in the context of  research .

    Recommendation ID IPG651/2 Question Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis

  3. How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy? Focal seizures: carbamazepine, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin  and zonisamide. Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide.

    Recommendation ID CG137/1 Question How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy

  4. Current evidence on the safety and efficacy of radially emitting laser fibre treatment of an anal fistula is limited in quantity and quality. Therefore, although there are no major safety concerns, this procedure should only be used with special arrangements  for clinical governance, consent, and audit or research.

    Recommendation ID IPG644/1 Question Current evidence on the safety and efficacy of radially emitting laser fibre treatment of an anal fistula

  5. The evidence on the safety of reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia shows there are serious but well-recognised complications. The evidence on efficacy is limited in quantity and quality. Therefore, this procedure should not be used unless  special arrangements   are in place for clinical governance, consent, and audit or research.

    Recommendation ID IPG654/1 Question The evidence on the safety of reinforcement of a permanent stoma with a synthetic or biological mesh

  6. Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised complications including skin burns. The evidence on efficacy is limited in quality. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG657/1 Question Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound

  7. The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG656/1 Question The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder

  8. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    Evidence-based recommendations on rucaparib (Rubraca) for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has

  9. Rapid tests for group A streptococcal infections in people with a sore throat (DG38)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat